These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25350385)

  • 1. Ex vivo treatment response of primary tumors and/or associated metastases for preclinical and clinical development of therapeutics.
    Corben AD; Uddin MM; Crawford B; Farooq M; Modi S; Gerecitano J; Chiosis G; Alpaugh ML
    J Vis Exp; 2014 Oct; (92):e52157. PubMed ID: 25350385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiologically relevant in vitro tumor models for drug screening.
    Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
    Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Ricciardelli C; Lokman NA; Sabit I; Gunasegaran K; Bonner WM; Pyragius CE; Macpherson AM; Oehler MK
    Cancer Lett; 2018 May; 421():51-58. PubMed ID: 29425684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment.
    Yoshii Y; Furukawa T; Waki A; Okuyama H; Inoue M; Itoh M; Zhang MR; Wakizaka H; Sogawa C; Kiyono Y; Yoshii H; Fujibayashi Y; Saga T
    Biomaterials; 2015 May; 51():278-289. PubMed ID: 25771018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade.
    Xu R; Richards FM
    Comb Chem High Throughput Screen; 2017; 20(5):451-457. PubMed ID: 28155598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance.
    Singh A; Brito I; Lammerding J
    Trends Cancer; 2018 Apr; 4(4):281-291. PubMed ID: 29606313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from patient-derived xenografts for better in vitro modeling of human cancer.
    Choi SY; Lin D; Gout PW; Collins CC; Xu Y; Wang Y
    Adv Drug Deliv Rev; 2014 Dec; 79-80():222-37. PubMed ID: 25305336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment.
    Holton AB; Sinatra FL; Kreahling J; Conway AJ; Landis DA; Altiok S
    PLoS One; 2017; 12(1):e0169797. PubMed ID: 28085924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
    Teicher BA
    Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
    Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
    Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the Histoculture Drug Response Assay (HDRA).
    Hoffman RM; Vescio RA
    Methods Mol Biol; 2018; 1760():39-48. PubMed ID: 29572792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
    Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
    Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy.
    Blom K; Nygren P; Alvarsson J; Larsson R; Andersson CR
    J Lab Autom; 2016 Feb; 21(1):178-87. PubMed ID: 26246423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.
    Santo VE; Rebelo SP; Estrada MF; Alves PM; Boghaert E; Brito C
    Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27966285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ex-vivo-chemoresponse testing of head and neck cancer: an old hat?].
    Wichmann G; Körner C; Dietz A
    Laryngorhinootologie; 2011 Aug; 90(8):464-8. PubMed ID: 21809229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular target class is predictive of in vitro response profile.
    Greshock J; Bachman KE; Degenhardt YY; Jing J; Wen YH; Eastman S; McNeil E; Moy C; Wegrzyn R; Auger K; Hardwicke MA; Wooster R
    Cancer Res; 2010 May; 70(9):3677-86. PubMed ID: 20406975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.
    Carvalho MR; Lima D; Reis RL; Oliveira JM; Correlo VM
    Stem Cell Rev Rep; 2017 Jun; 13(3):347-363. PubMed ID: 28233276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mini-pillar array for hydrogel-supported 3D culture and high-content histologic analysis of human tumor spheroids.
    Kang J; Lee DW; Hwang HJ; Yeon SE; Lee MY; Kuh HJ
    Lab Chip; 2016 Jun; 16(12):2265-76. PubMed ID: 27194205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.